Drugs in development for influenza

Drugs

Volumn 70, Issue 11, 2010, Pages 1349-1362

  Boltz, David A ^a   Aldridge, Jerry R ^a   Webster, Robert G ^a   Govorkova, Elena A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Amantadine, therapeutic use; DAS 181, therapeutic use; Favipiravir, therapeutic use; Influenza virus infections, treatment; Laninamivir, therapeutic use; Nitazoxanide, therapeutic use; Nonsteroidal anti inflammatories, therapeutic use; Oseltamivir, therapeutic use; Peramivir, therapeutic use; Research and development; Rimantadine, therapeutic use; Thiazolidinediones, therapeutic use; Zanamivir, therapeutic use

Indexed keywords

ADAMANTANE DERIVATIVE; AMANTADINE; ANTIVIRUS AGENT; CELECOXIB; CS 8958; CYANOVIRIN N; CYCLOOXYGENASE 2 INHIBITOR; DAS 181; DRUG METABOLITE; FAVIPIRAVIR; FIBRIC ACID DERIVATIVE; FUSION PROTEIN INHIBITOR; GEMFIBROZIL; GLITAZONE DERIVATIVE; IMMUNOMODULATING AGENT; INFLUENZA VACCINE; LANINAMIVIR; MESALAZINE; NITAZOXANIDE; OSELTAMIVIR; PERAMIVIR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; R 118958; R 125489; RIBAVIRIN; RIMANTADINE; RNA POLYMERASE INHIBITOR; SIALIDASE INHIBITOR; SMALL INTERFERING RNA; THIAZOLIDE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANAMIVIR; IMMUNOLOGIC FACTOR; NEW DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; INFECTION CONTROL; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; NONHUMAN; PANDEMIC; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG EFFECTS; INFLUENZA, HUMAN; MALE; MOUSE; ORTHOMYXOVIRIDAE INFECTIONS; ORTHOMYXOVIRUS; PHYSIOLOGY; VIROLOGY;

ORTHOMYXOVIRIDAE;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOLOGIC FACTORS; INFLUENZA, HUMAN; MALE; MICE; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 77954559469     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11537960-000000000-00000     Document Type: Review

References (118)

1. Glezen WP, Greenberg SB, Atmar RL, et al. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 2000; 283 (4): 499-505
2. Chan MC, Cheung CY, Chui WH, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 2005; 6: 135
3. Kash JC, Tumpey TM, Proll SC, et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 2006; 443 (7111): 578-581
4. Loo YM, Gale Jr M. Influenza: fatal immunity and the 1918 virus. Nature 2007; 445 (7125): 267-268
5. Monto AS. The role of antivirals in the control of influ-enza. Vaccine 2003; 21 (16): 1796-1800
6. Sidwell RW, Huffman JH, Barnard DL, et al. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 1998; 37 (2): 107-120
7. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis 1999; 180 (2): 254-261
8. McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med 2005; 4 (2): 107-116
9. Hay AJ, Wolstenholme AJ, Skehel JJ, et al. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985; 4 (11): 3021-3024
10. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 1992; 69 (3): 517-528
11. Hayden FG. Amantadine and rimantadine: clinical aspects. In: Richman DD, editor. Antiviral drug resistance. New York: John Wiley & Sons, Inc., 1996: 59-77
12. Wang C, Takeuchi K, Pinto LH, et al. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 1993; 67 (9): 5585-5594
13. Grambas S, Hay AJ. Maturation of influenza A virus he-magglutinin: estimates of the pH encountered during transport and its regulation by the M2 protein. Virology 1992; 190 (1): 11-18
14. Betakova T, Ciampor F, Hay AJ. Influence of residue 44 on the activity of the M2 proton channel of influenza A virus. J Gen Virol 2005; 86 Pt 1: 181-184
15. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363 (6428): 418-423
16. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000; 355 (9206): 827-835
17. Roberts NA, Govorkova EA. The activity of neura-minidase inhibitor oseltamivir against all subtypes of influenza viruses. In: Mitrasinovic PM, editor. Global view of the fight against influenza. New York: Nova Science Publishers, 2009: 93-118
18. Bright RA, Medina MJ, Xu X, et al. Incidence of ada-mantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366 (9492): 1175-1181
19. Monto AS, McKimm-Breschkin JL, Macken C, et al. De-tection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50 (7): 2395-2402
20. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Sur-veillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52 (9): 3284-3292
21. Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-re-sistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009; 15 (4): 552-560
22. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009; 301 (10): 1034-1041
23. Hurt AC, Ernest J, Deng YM, et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009; 83 (1): 90-93
24. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009; 360 (10): 953-956
25. Deyde VM, Sheu TG, Trujillo AA, et al. Detection of molecular markers of drug resistance in the 2009 pandemic influenza A (H1N1) viruses using pyrosequencing. Antimicrob Agents Chemother 2010; 54 (3): 1102-1110
26. Centers for Disease Control and Prevention (CDC). Up-date: influenza activity. United States, August 30-October 31, 2009. MMWR Morb Mortal Wkly Rep 2009; 58(44): 1236-1241
27. Le QM, Wertheim HF, Tran ND, et al. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 2010; 362 (1): 86-87
28. Gaur AH, Bagga B, Barman S, et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010; 362 (1): 88-89
29. Chen H, Cheung CL, Tai H, et al. Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg Infect Dis 2009; 15 (12): 1970-1972
30. Babu YS, Chand P, Bantia S, et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 2000; 43 (19): 3482-3486
31. Bantia S, Parker CD, Ananth SL, et al. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemo-ther 2001; 45 (4): 1162-1167
32. Drusano GL, Preston SL, Smee D, et al. Pharmacodyna-mic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. Antimicrob Agents Chemo-ther 2001; 45 (7): 2115-2118
33. Smee DF, Huffman JH, Morrison AC, et al. Cyclopentane neuraminidase inhibitors with potentinvitro anti-influenza virus activities. Antimicrob Agents Chemother 2001; 45 (3): 743-748
34. Sidwell RW, Smee DF, Huffman JH, et al. In vivo influ-enza virus-inhibitory effects of the cyclopentane neura-minidase inhibitor RJW-270201. Antimicrob Agents Chemother 2001; 45 (3): 749-757
35. Govorkova EA, Leneva IA, Goloubeva OG, et al. Com-parison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001; 45 (10): 2723-2732
36. Barroso L, Treanor J, Gubareva L, et al. Efficacy and tol-erability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 2005; 10 (8): 901-910
37. Kilpatrick JM, Harman LA, Collis PJ, et al. Pharmaco-kinetics and safety of peramivir by intramuscular administration [abstract no. P916]. In: Program and abstracts of the Options for the Control of Influenza VI Conference (Toronto). London: International Society for Influenza and Other Respiratory Virus Diseases, 2007
38. Beigel J, Harman LA, Collis PJ, et al. Pharmacokinetic and safety evaluations of escalating doses of peramivir administered intravenously in healthy volunteers [poster no. A-1408]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
39. Bantia S, Arnold CS, Parker CD, et al. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 2006; 69 (1): 39-45
40. Boltz DA, Ilyushina NA, Arnold CS, et al. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res 2008; 80 (2): 150-157
41. Yun NE, Linde NS, Zacks MA, et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 2008; 374 (1): 198-209
42. Ison MG, McGeer AJ, Hui DS, et al. Safety and efficacy of multiple-day treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza [abstract]. XI International Symposium on Respiratory Viral Infections; 2009 Feb 19-22; Bangkok
43. Kohno S, Yen MY, Cheong HJ, et al. Single-intravenous peramivir vs. oral oseltamivir to treat acute, uncomplicated influenza in the outpatient setting: a phase III randomized, double-blind trial [abstract no. V-537a]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12-15; San Francisco (CA)
44. BioCryst Pharmaceuticals. BioCryst pharmaceuticals re-ports positive results of Shionogi & Co. sponsored phase 3 studies of i.v. peramivir for influenza [press release]. 17 July 2009 [online]. Available from URL: http://investor. shareholder.com/biocryst/ReleaseDetail.cfm?ReleaseID= 397310 [Accessed 2010 Jan 20]
45. U.S. Food and Drug Administration. Emergency use authori-zation of peramivir iv fact sheet for health care providers [online]. Available from URL: http://www.fda.gov/down loads/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/UCM 187811.pdf [Accessed 2010 Jan 21]
46. Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res 2007; 74 (2): 159-162
47. Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother 2009; 53 (10): 4433-4440
48. BioCryst Pharmaceuticals. Biocryst provides peramivir update and reports first quarter 2009 financial results [press release]. 8 May 2009 [online]. Available from URL: http://investor.shareholder.com/biocryst/releasedetail. cfm?ReleaseID=382718 [Accessed 2010 Jan 20]
49. Memoli MJ, Hrabal RJ, Hassantoufighi A, et al. Rapid selection of oseltamivir-and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010; 50 (9): 1252-1255
50. Stittelaar KJ, Tisdale M, van Amerongen G, et al. Evalua-tion of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. Antiviral Res 2008; 80 (2): 225-228
51. Calfee DP, Peng AW, Cass LM, et al. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999; 43 (7): 1616-1620
52. Kidd IM, Down J, Nastouli E, et al. H1N1 pneumonitis treated with intravenous zanamivir. Lancet 2009; 374 (9694): 1036
53. GlaxoSmithKline. An open-label, multi-center, single arm study to evaluate the safety and tolerability of intravenous zanamivir in the treatment of hospitalized adult, adolescent and pediatric subjects with confirmed influenza infection [online]. Available from URL: http://www.gsk- clinicalstudyregister.com/protocol-detail.jsp?protocolId= 113678&studyId= 29102&compound=Zanamivir [Accessed 2010 Jan 10]
54. Honda T, Kubo S, Masuda T, et al. Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. Bioorg Med Chem Lett 2009; 19 (11): 2938-2940
55. Koyama K, Takahashi M, Oitate M, et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother 2009; 53 (11): 4845-4851
56. Yamashita M, Tomozawa T, Kakuta M, et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Anti-microb Agents Chemother 2009; 53 (1): 186-192
57. Kubo S, Tomozawa T, Kakuta M, et al. Laninamivir pro-drug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother 2010; 54 (3): 1256-1264
58. Rennecke J, Hirota T, Puchler K, et al. R-118958, a unique anti-influenza agent: safety, tolerability and pharmaco-kinetics (PK) in healthy male volunteers [abstract no. F-1834]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Washington, DC
59. Biota. LANI phase III clinical trials in Asia prove suc-cessful [online]. Available from URL: http://www.biota. com.au/uploaded/154/1021542- 25laniphaseiiiclinicaltri.pdf [Accessed 2009 Dec 27]
60. Biota. Phase III trial with CS-8958 for flu prevention un-derway [online]. Available from URL: http://www.biota. com.au/uploaded/154/1021585- 54cs8958phaseiiipreventio. pdf [Accessed 2009 Dec 27]
61. Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002; 46 (4): 977-981
62. Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mecha-nism of action of T-705 against influenza virus. Anti-microb Agents Chemother 2005; 49 (3): 981-986
63. Gowen BB, Wong MH, Jung KH, et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 2007; 51 (9): 3168-3176
64. Streeter DG, Witkowski JT, Khare GP, et al. Mechanism of action of 1-b-D-ribofuranosyl-1,2,4-triazole-3-carbox-amide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci USA 1973; 70 (4): 1174-1178
65. Takahashi K, Furuta Y, Fukuda Y, et al. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir Chem Chemother 2003; 14 (5): 235-241
66. Fujifilm. Notice of start of phase III clinical trials of T-705 as a treatment for influenza infections in Japan [online]. Available from URL: http://www.fujifilmholdings.com/en/pdf/inve
67. Furuta Y, Takahashi K, Shiraki K, et al. T-705 (favipir-avir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009; 82 (3): 95-102
68. O'Keefe BR, Smee DF, Turpin JA, et al. Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob Agents Chemother 2003; 47 (8): 2518-2525
69. Smee DF, Bailey KW, Wong MH, et al. Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antiviral Res 2008; 80 (3): 266-271
70. Smee DF, Wandersee MK, Checketts MB, et al. Influenza A (H1N1) virus resistance to cyanovirin-N arises naturally during adaptation to mice and by passage in cell culture in the presence of the inhibitor. Antivir Chem Chemother 2007; 18 (6): 317-327
71. Igarashi M, Ito K, Yoshida R, et al. Predicting the anti-genic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin. PLoS One 2010; 5 (1): e8553
72. Malakhov MP, Aschenbrenner LM, Smee DF, et al. Siali-dase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50 (4): 1470-1479
73. Chan RW, Chan MC, Wong AC, et al. DAS181 inhi-bits H5N1 influenza virus infection of human lung tissues. Antimicrob Agents Chemother 2009; 53 (9): 3935-3941
74. Triana-Baltzer GB, Gubareva LV, Nicholls JM, et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One 2009; 4 (11): e7788
75. Triana-Baltzer GB, Babizki M, Chan MC, et al. DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis. J Antimicrob Chemother 2010; 65 (2): 275-284
76. Triana-Baltzer GB, Gubareva LV, Klimov AI, et al. In-hibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One 2009; 4 (11): e7838
77. NexBio. NexBio initiates phase II trial of DAS181 (Fludase®*) for treatment of influenza, including pandemic influenza A(H1N1) [online]. Available from URL: http://www.nexbio.com/docs/DAS181-Phase-2-Press- Release-010710.pdf [Accessed 2010 Jan 24]
78. Rossignol JF, La Frazia S, Chiappa L, et al. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009; 284 (43): 29798-29808
79. Ge Q, McManus MT, Nguyen T, et al. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci USA 2003; 100 (5): 2718-2723
80. Tompkins SM, Lo CY, Tumpey TM, et al. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci USA 2004; 101 (23): 8682-8686
81. Zhou H, Jin M, Yu Z, et al. Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice. Antiviral Res 2007; 76 (2): 186-193
82. Zhang W, Wang CY, Yang ST, et al. Inhibition of highly pathogenic avian influenza virus H5N1 replication by the small interfering RNA targeting polymerase A gene. Biochem Biophys Res Commun 2009; 390 (3): 421-426
83. Karlas A, Machuy N, Shin Y, et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 2010; 463 (7282): 818-822
84. Konig R, Stertz S, Zhou Y, et al. Human host factors re-quired for influenza virus replication. Nature 2010; 463 (7282): 813-817
85. Hao L, Sakurai A, Watanabe T, et al. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 2008; 454 (7206): 890-893
86. Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis 2008; 8 (9): 571-576
87. Budd A, Alleva L, Alsharifi M, et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother 2007; 51 (8): 2965-2968
88. Aldridge Jr JR, Moseley CE, Boltz DA, et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci USA 2009; 106 (13): 5306-5311
89. Lin KL, Suzuki Y, Nakano H, et al. CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J Immunol 2008; 180 (4): 2562-2572
90. Lee SM, Cheung CY, Nicholls JM, et al. Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. J Infect Dis 2008; 198 (4): 525-535
91. Carey MA, Bradbury JA, Seubert JM, et al. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J Immunol 2005; 175 (10): 6878-6884
92. Zheng BJ, Chan KW, Lin YP, et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008; 105 (23): 8091-8096
93. Pfeiffer JK, Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA 2003; 100 (12): 7289-7294
94. Pfeiffer JK, Kirkegaard K. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J Virol 2005; 79 (4): 2346-2355
95. Shinya K, Ebina M, Yamada S, et al. Avian flu: influenza virus receptors in the human airway. Nature 2006; 440 (7083): 435-436
96. Korba BE, Montero AB, Farrar K, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008; 77 (1): 56-63
97. Rossignol JF, Keeffe EB. Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. Future Microbiol 2008; 3: 539-545
98. Rossignol JF, Abu-Zekry M, Hussein A, et al. Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet 2006; 368 (9530): 124-129
99. Rossignol JF, Elfert A, El-Gohary Y, et al. Improved vir-ologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastro-enterology 2009; 136 (3): 856-862
100. Korba BE, Elazar M, Lui P, et al. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother 2008; 52 (11): 4069-4071
101. Hannon GJ. RNA interference. Nature 2002; 418 (6894): 244-251
102. DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008; 77 (3): 225-231
103. Alnylam. ALN-RSV: respiratory syncytial virus [online]. Available from URL: http://www.alnylam.com/Programs-and-Pipeline/Programs/index.php [Accessed 2010 Jan 28]
104. Galabov AS, Simeonova L, Gegova G. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice. Antivir Chem Chemother 2006; 17 (5): 251-258
105. Govorkova EA, Fang HB, Tan M, et al. Neuramini-dase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 2004; 48 (12): 4855-4863
106. Ilyushina NA, Hoffmann E, Salomon R, et al. Amanta-dine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 2007; 12 (3): 363-370 (Pubitemid 46787981)
107. Masihi KN, Schweiger B, Finsterbusch T, et al. Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice. J Chemother 2007; 19 (3): 295-303
108. Ilyushina NA, Hay A, Yilmaz N, et al. Oseltamivir-riba-virin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 2008; 52 (11): 3889-3897
109. Nguyen JT, Hoopes JD, Le MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010; 5 (2): e9332
110. Nguyen JT, Hoopes JD, Smee DF, et al. Triple combina-tion of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 2009; 53 (10): 4115-4126
111. Ilyushina NA, Bovin NV, Webster RG, et al. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 2006; 70 (3): 121-131
112. Basler CF. Influenza viruses: basic biology and poten-tial drug targets. Infect Disord Drug Targets 2007; 7 (4): 282-293
113. Cheung CY, Poon LL, Lau AS, et al. Induction of pro-inflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002; 360 (9348): 1831-1837
114. Kobasa D, Jones SM, Shinya K, et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 2007; 445 (7125): 319-323
115. Fedson DS. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 2009; 3 (4): 129-142
116. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intesti-nal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med 2005; 201 (8): 1205-1215
117. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008; 454 (7203): 470-477
118. Di Gregorio GB, Yao-BorengasserA,RasouliN,etal. Expres-sion of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pio-glitazone. Diabetes 2005; 54 (8): 2305-13